

References

Adam O, Frost G, Custodis F, et al. (2007): Role of Rac1 GTPase activation in atrial fibrillation. *J Am Coll Cardiol*; 50: 359-367.

Allred AJ, Diz DI, Ferrario CM, Chappell MC (2000): Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. *Am J Physiol* 279: F841-F850.

Alrefai H, Allababidi H, Levy S, and Levy J (2002): The Endocrine System in Diabetes Mellitus. *Endocrine* 18; 105.

Ambrosioni E, Borghi C, Magnani B, et al. (1995): For the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. *N Engl J Med*; 332: 80.

American Diabetes Association (2002): The prevention or delay of type 2 diabetes. *Diabetes Care*; 25: 742-9.

American Heart Association (2004): Heart disease and stroke statistics – 2005 Update. Dallas, Tex: American Heart Association.

References

- Andraws R, Brown DL. (2007):** Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). *Am J Cardiol*; 99: 1006-12.
- Arnett DK, Davis BR, Ford CE, et al. (??):** Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood ??
- Asano K, Dutcher DL, Port D, et al. (2000):** Selective downregulation of the angiotensin II AT1-receptor subtype in the failing human ventricular myocardium. *Circulation*; 95: 1193.
- Asbert M, Jimenez W, Gaya J, Gines P, Arroyo V, Rivera F and Rodes J (1992):** Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin. *J Hepatol*; 15: 1-2, 179-83.
- ASPIRE HIGHER** clinical program expands to 35.000 patients in 14 trials, the largest cardio-renal outcomes program ever.
<http://www.novartis.com/newsroom/mediareleases/en/2008/1228485.shtml> June 17.
- Azizi M, Ezan E, Nicolet L, Grognet J-M, Menard J (1997):** High plasma level of A'-Acetyl-Seryl-Aspartyl-Lysyl-Prolifile: A new marker of chronic angiotensin-converting enzyme inhibition. *Hypertension* 30: 1015-1019

References

- Azizi M, Menard J, Bissery A, et al. (2004):** Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. *J Am Soc Nephrol*; 15: 3126-33.
- Bader M (2002):** Role of the local renin-angiotensin system in cardiac damage: a minireview focusing on transgenic animal models. *Journal of Molecular and Cellular Cardiology*; 34: 1455-1462.
- Bader M, Peters J, Baltatu O, et al. (2001):** Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. *Journal of Molecular Medicine*; 79: 76-102.
- Badorff C, Ruetten H, Mueller S, et al. (2002):** Fas receptor signaling inhibits glycogen synthase kinase 3 β and induces cardiac hypertrophy following pressure overload. *Journal of Clinical Investigation*; 109: 373-381.
- Baker KM, Chernin MI, Wixson SK, et al. (1995):** Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. *Am J Physiol*; 259: H324.
- Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA and Rippe RA (2005):** Systemic infusion of angiotensin II exacerbates liver

References

fibrosis in bile duct-ligated rats. *Hepatology*; 41(5): 1046-55.

Bataller R, Sancho-Bru P, Gines P and Brenner DA (2005): Liver fibrogenesis: a new role for the renin-angiotensin system. *Antioxid Redox Signal*; 7(9-10): 1346-55.

Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ and Brenner DA (2003): NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *J Clin Invest*; 112(9): 1383-94.

Bauer JH, Reams GP (1995): The angiotensin II type 1 receptor antagonist. A new class of antihypertensive drugs. *Arch Intern Med*; 155: 1361.

Bayorh MA, Mann G, Walton M, Eatman D (2006): Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats. *Clin and Exper Hypertension* 28: 121-32

Beldent V, Michaud A, Wei L, Chauvet M-T, Corvol P, (1993): Proteolytic release of human angiotensin-converting enzyme: localization of the cleavage site. *J Biol Chem* 268: 26428-26434

Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI (2006): Angiotensin-(1-7) prevents development of severe

References

hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. *Am J Physiol* 290: H684-H691

Benter IF, Yousif MHM, Cojocel C, Al-Maghrebi M, Diz DI (2007): Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. *Am J Physiol* 292: H666—H672

Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R (1999): Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. *Circulation* 99: 2034-2040

Berry C, Touyz R, Dominiczak AF, et al. (2001): Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. *American Journal of Physiology; Heart and Circulatory Physiology*; 281: H2337-H2365.

Berry C, Touyz R, Dominiczak AF, et al. (2002): Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. *Am J Physiol Heart Circ Physiol*; 281(6): H2337-65.

Blaufarb IS, Sonnenblick EH (1996): The renin-angiotensin system in left ventricular remodeling. *Am J Cardiol*; 77: 8C-16C.

References

- Boehm M, Nabel EG (2000):** Angiotensin-converting enzyme-2- a new cardiac regulator. *N Engl J Med*; 347: 1795.
- Boldt A, Wetzel U, Weigl J, et al. (2003):** Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. *J Am Coll Cardiol*; 42: 1785-1792.
- Booth RE, Johnson JP, and Stockand JD (2002):** Aldosterone. *Advances in Physiology Education* 26; 8.
- Booz GW and Baker KM (1996):** The role of the renin-angiotensin system in the pathophysiology of cardiac remodeling. *Blood Pressure*; 5(Suppl 2), 10-18.
- Booz GW and Baker KM (1998):** Actions of angiotensin II on isolated cardiac myocytes. *Heart Failure Reviews*; 3: 125-130.
- Booz GW, Conrad KM, Hess AL, et al. (1992):** Angiotensin-II-binding sites on hepatocyte nuclei. *Endocrinology*; 130: 3641-3649.
- Booz GW, Dostal DE and Baker KM (1999):** Paracrine actions of cardiac fibroblasts on cardiomyocytes: implications for the cardiac renin-angiotensin system. *American Journal of Cardiology*; 83: 44H-47H.
- Bosch J, Yusuf S, Gerstein HC et al. (2006):** Effect of ramipril on the incidence of diabetes. *S Engl J Med*; 355: 1551 -62.

References

- Brasier AR, Li J and Copland A (1994):** Transcription factors modulating angiotensinogen gene expression in hepatocytes. *Kidney Int*; 46(6): 1564-6.
- Braunwald E, Domanski MJ, Fowler SE et al. (2004):** Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*; 351: 2058-68.
- Brenner and Rector's (2004):** The kidney, 7th ed., Saunders.
- Brenner BM et al. (2001):** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*; 345: 861-869.
- Brenner BM, Cooper ME, de Zeeuw D et al. (2001):** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*; 345: 861-9.
- Brenner BM, Cooper ME, de Zeeuw D et al. (2001):** Renal study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*; 345: 861-9.
- Brewster UC, Setaro JF, Perazella MA (2003):** The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. *Am J Med Sci*; 326: 15-24.
- Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Penninger JM, Ferrario CM (2003):** Enhanced renal

References

immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 42: 749-753

Buchanan TA, Xiang AH, Peters RK et al. (2002): Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes; 51:2796-803.

Burckle CA, Danser AHJ, Muller D, Garrelds IM, Gasc JM, Popova E, Pleham R, Peters J, Bader M, Nguyen G (2006): Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47: 552-556

Burlew BS and Weber KT (2000): Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiology Clinics; 18: 435-442.

Burnier M (2001): Angiotensin II type 1 receptor blockers. Circulation: 103: 904.

Burnier M (2001): Angiotensin II type I receptor blockers. Circulation; 103.

Burns KD (2000): Angiotensin IT and its receptors in the diabetic kidney. American Journal of Kidney Diseases 36: 449-467

Butz S, Driamov S, Remondino A, et al. (2004): Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-

References

flow ischaemia. *J Pharm Pharmacol*; 56: 521-528.

Cames CA, Chung MK, Nakayama T, et al. (2001): Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res*; 89: E32-E38.

Campbell DJ, Aggarwal A, Esler M, Kaye D (2001): Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. *Lancet*; 358: 1609-10.

Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, Bernstein KE (2004): Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. *Hypertension* 43: 854-859

Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA (1998): Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. *Journal of Pharmacology & Experimental. Therapeutics*. 287: 567-577

Carey RM, Siragy HM (2003): Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. *Endocr Rev*; 24: 261-271.

References

- Carey RM, Siragy HM (2003):** Newly recognized components of the Renin-Angiotensin system: potential roles in cardiovascular and renal regulation. *Endocr. Rev* 24: 261—271
- Caskey FJ, Thacker EJ, Johnston PA, et al. (1997):** Failure of losartan to control blood pressure in scleroderma renal crisis. *Lancet*; 349: 620.
- Cassiman D and Roskams T (2002):** Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. *J Hepatol*; 37(4): 527-35.
- Cavasin MA, Nour-Eddine R, Yang X-P, Carretero OA (2004):** Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. *Hypertension* 43: 1140-1145
- Ceconi C et al. (2007):** ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. *Cardiovasc Res*; 73(1): 237-246.
- Celentano A, Mancini FP, Crivaro M, et al. (1999):** Cardiovascular risk factors angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. *Am J Cardiol*; 83: 1196.
- Chappell MC, Allred AJ, Ferrario CM (2001):** Pathways of angiotensin-(1-7) metabolism in the kidney. *Nephrol Dial*

References

Transplant 16: 22—26

Chappell MC, Ferrario CM (1999): Angiotensin-(1-7) in hypertension. *Curr. Opin. Nephrol. Hypertens.* 88: 231-235

Chappell MC, Gomez MN, Pirro NT, Ferrario CM (2000): Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. *Hypertension* 35: 348-352

Chappell MC, Modrall JG, Diz DI, Ferrario CM (2004): Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. In *Kidney and Blood Pressure Regulation*, ed. H Suzuki, T Saruta, 77-89. Basel, Karger

Chen J et al. (2004): The metabolic syndrome and chronic kidney disease in US Adults. *Annals of Internal Medicine*; 140(3): 167-175.

Chen Z, Tan F, Erdos EG, Deddish PA (2005): Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B₂ kinin receptors. *Hypertension* 46: 1368-1373

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. *Lancet*; 359: 2072-7.

References

- Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003):** Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*; 290: 486-94.
- Cicoira M, Zanolla L, Rossi A (2001):** Failure of aldosterone suppression despite angiotensin converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. *J Am Coll Cardiol*; 37: 1808.
- Clark MA, Diz DI, Tallant EA (2001):** Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. *Hypertension* 37: 1141-1146
- Clark MA, Tallant EA, Tommasi EN, Bosch SM, Diz DI (2003):** Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase dependent pathway. *J. Cardiovasc. Pharmacol.* 41: 276-283.
- Clcoira M, Zanolla L, Rossi A, et al. (2001):** Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with Ace DD genotype. *J Am Coll Cardiol*; 37: 1808.
- Cleland JGF, Henderson E, McLenachan J. et al. (1991):** Effect of captopril, an angiotensin converting enzyme inhibitor, in

References

patients with angina pectoris and heart failure. J Am Coll Cardiol; 17:733.

Cline GW, Petersen KF, Krssak M et al. (1999): Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med; 341: 240-6.

Cohn JN, Anand IS, Latini R et al. (2003): Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation; 108: 1306-09.

Cohn JN, Johnson G. Ziesche S, et al. (1991): A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med; 325: 303.

Cohn JN, Tognoni G (2001): Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med; 345: 1667-75.

Collister JP and Hendel MD (2003): The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst; 4(3): 176-9.

References

CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med*; 316:1429.

Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C and Rosmorduc O (2002): Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. *Hepatology*; 35(5): 1010-21.

Cowie MR, Mosterd A, Wood DA et al. (1997): The epidemiology of heart failure. *Eur Heart J*; 18: 208-25.

Crabos M, Roth M, Hahn AW, et al. (1994): Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. *J Clin Invest*; 93: 2372-2378.

Crackower MA, Sarao R, Oudit GY, et al. (2002): Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature*; 417: 822.

Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Bray MR, Backx PH, Chappell MC, Yagil Y, Penninger JM (2002): Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 417: 822-828

References

Cushman DW, Ondetti MA (1999): Design of angiotensin converting enzyme inhibitors. *Nat Med*; 5:1110-13.

Dahlof B, Devereux RB, Kjeldsen SE et al. (2002): Cardiovascular morbidity and mortality in the Losaran Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*; 359: 995-1003.

Dahlof B, Devereux RB, Kjeldsen SE et al. (2002): Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*; 359: 995-1003.

Dahlof B, Devereux RB, Kjeldsen SE, et al. (2002): Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*; 359: 995.

Dahlof B, Hansson L, Lindholm LH et al. (1993): STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. *Swedish Trial in Old Patients with Hypertension. Blood Press*; 2:136-41.

Dal Ponte DB, Fogt DL, Jacob S, Henriksen EJ (1998): Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. *Metabolism*; 47: 982-7.

References

- Danser AH, Deinum J (2005):** Renin, prorenin and the putative (pro)renin receptor. *Hypertension*; 46: 1069-76.
- Danser AH, van den Dorpel MA, Deinum J et al. (1989):** Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. *J Clin Endocrinol Metab*; 68: 160-7.
- Danser AHJ, Charney A, Feldman DL, Nussberger D, Fisher ND, Hollenberg NK (2008):** The renin rise with aliskiren: it's simply stoichiometry. *Hypertension*; 51: e27-8.
- Danser AHJ, Schalekamp MADH, Bax WA, et al. (1999):** Angiotensin-converting enzyme in the human heart: effect of the deletion/ insertion polymorphism. *Circulation*; 92: 1387.
- Danser AHJ, van Kesteren CA, Bax WA et al. (1997):** Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. *Circulation*; 96: 220-6.
- Daugherty A, Manning MW, Cassis LA (2000):** Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest*; 105: 1605.
- Davis JO, Freeman RH (1976):** Mechanisms regulating renin release. *Physiol Rev*; 56: 1.

References

- de Boer RA, Pokharel S, Flesch M, et al. (2004):** Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR (mRen2) 27. J Mol Med; 82: 678-87.
- de Gasparo M, Catt KJ, Inagami T, et al. (2000):** International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev; 52: 415-472.
- De Mello WC (1998):** Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension; 32: 976-982.
- Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG (1998):** N-domain specific substrate and C-domain inhibitors of angiotensin converting enzyme. Hypertension 31: 912-917
- DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP (1981):** The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes; 30: 1000-07.
- Dendorfer A, Dominiak P, Schunkert H (2005):** ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol; 170: 407-42.

References

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*; 346: 393-403.

Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ (1996): Potential role of bradykinin in forearm muscle metabolism in humans. *Diabetes*; 45(suppl 1): S110-S114.

Diez J, Lopez B, Gonzalez B and Querejeta R (2001): Clinical aspects of hypertensive myocardial fibrosis. *Current Opinion in Cardiology*; 16: 328-335.

Diez J, Querejeta R, Lopez B, et al. (2002): Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. *Circulation*; 105: 2512-2517.

Diez-Freire C, Vasquez J, Correa de Adjounian MF, Ferrari MFR, Yuan L, Silver X, Torres R, Raizada MK (2006): ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. *Physiol Genomics* 27: 12-19

Dikalova A, Clempus R, Lassegue B, et al. (2005): Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. *Circulation*; 112: 2668.

References

Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniassse P, Corvol P (1999): RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Nad. Acad. Sci. USA 96: 4330-4335

Donoghue M, Hsieh F, Baronas E, et al. (2000): A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res; 87: E1.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robinson K, Jeyaseelan R, Breitbart RE, Acton S (2000): A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I "to angiotensin 1-9. Circ Res 87: E1-E9

Dostal DE and Baker KM (1992): Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. American Journal of Hypertension; 5: 276-280.

Dostal DE, Baker KM (1999): The cardiac renin-angiotensin system: conceptual or a regulator of cardiac function? Circ Res; 85: 643.

References

- Dostal DE, Booz GW and Baker KM (2000):** Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and β -adrenergic stimulation. *Basic Research in Cardiology*; 95: 485-491.
- Dzau VJ, Gibbons GH, Pratt RE (1999):** Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. *Hypertension*; 18: II100.
- Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M, (2006):** New mass spectrometric assay for angiotensin-converting enzyme 2 activity. *Hypertension* 47: 1010-1017
- Engeli S and Sharma AM (2001):** The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. *J Mol Med*; 79: 21-29.
- Engeli S and Sharma AM (2002):** Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. *Curr Opin Cardiol*; 17: 355-359.
- Engeli S, Schling P, Gorzelniak K et al. (2003):** The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? *Int J Biochem Cell Biol*; 35: 807-25.
- Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H,**

References

- Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N and Thurman RG (2000):** Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. *J Gastroenterol Hepatol*; 15 (Suppl: D20-5.
- Eto K, Ohya Y, Nakamura Y, et al. (2002):** Intracellular angiotensin II stimulates voltage-operated Ca²⁺ channels in arterial myocytes. *Hypertension*; 39: 474-478.
- Faloia E, Gatti C, Camilloni MA et al. (2002):** Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. *J Endocrinol Invest*; 25: 309-14.
- Feldman DL, Jin L, Xuan H, et al. (2008):** Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2) 27 rats. *Hypertension*; 52: 130-6.
- Feldt S, Batenburg WW, Mazak I, et al. (2008):** Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. *Hypertension*; 51: 682-8.
- Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Carvalho MHC (2001):** Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. *Hypertension* 37: 703-709.

References

- Fernandez-Sola J, Nicolas JM, Oriola J, et al. (2002):** Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. *Ann Intern Med*; 137: 321.
- Ferner RE, Simpson JM, Rawlings MD (1987):** Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. *BMJ*; 294: 1119.
- Ferrannini E, Castaldelli A, Miyazaki Y et al. (2003):** Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. *Diabetologia*; 46: 1211-19.
- Ferrannini E, Seghieri C, Muscelli E (1994):** Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. *J Cardiovasc Pharmacol*; 24(suppl 3): S61-S69.
- Ferrario CM, Averill DA, Chappell MC, Brosnihan KB, Diz DI (2002b):** Vasopeptidase inhibition and angiotensin-(1-7) in the spontaneously hypertensive rat. *Kidney Int.* 62: 1349-57
- Ferrario CM, Jessup JA, Chappell MC, Averill DB, Brosnihan KB, Gallagher PE (2005a):** Effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin converting enzyme 2. *Circulation* 111: 2605-2610

References

- Ferrario CM, Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Chappell MC (2005b):** Effects of renin angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. *Kidney Int.* 68: 2189-2196
- Ferrario CM, Martell N, Yunis C, Hack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov S, Pinillas C, Luque M (1998):** Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. *Am. J. Hypertens.* 11: 137-146
- Ferrario CM, Smith RD, Brosnihan KB, Chappell MC, Campese VM, Vesterqvist O, Liao W, Ruddy MC, Grim CE (2002a):** Effects of omapatrilat on the renin angiotensin system in salt sensitive hypertension. *Am J Hypertens* 15: 557-564.
- Ferrario CM, Trask AJ, Jessup JA (2006):** Advances in biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in the regulation of cardiovascular function. *Am J Physiol* 289: H2281-H2290
- Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J (1985):** Captopril and insulin sensitivity. *Ann Intern Med*; 102:134-5.
- Filipeanu CM, Henning RH, de Zeeuw D and Nelemans A (2001):** Intracellular Angiotensin II and cell growth of vascular smooth muscle cells. *British Journal of*

References

Pharmacology; 132: 1590-1596.

Fogari R, Zoppi A, Corradi L, Lazzari R, Mugellini A, Lusardi R (1998): Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. *Br J Clin Pharmacol*; 46: 467-71.

Foianini KR, Steen MS, Kinnick TR, Schmit MB, Youngblood EB, Henriksen EJ (2000): Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle.; *Appl Physiol*; 89: 687-94.

Folli F, Kahn CR, Hansen H, Bouchie JL, Feener ER (1997): Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J Clin Invest*; 100: 2158-69.

Ford WR, Clanachan AS, Jugdutt BI (1996): Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia reperfusion in isolated working rat hearts. *Circulation*; 94: 3087.

Fox KM (2003): European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA

References

study). Lancet; 362: 782-788.

Francis GS, Benedict C, Johnstone DE, et al. (1990): Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation; 82: 1724-9.

Frustaci A, Kajstura J, Chimenti C, et al. (2000): Myocardial cell death in human diabetes. Circulation Research; 87: 1123-1132.

Furuhashi M, Ura N, Takizawa H et al. (2004): Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens; 22: 1977-82.

Gallagher PE, Chappell MC, Ferrario CM, Tallant EM (2006): Distinct roles for Ang II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol 290: C420-C426

Galletti F, Strazzullo R Capaldo B et al. (1999): Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry ' blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens; 17: 439-45.

Galliera E, Corsi MM, Bonecchi R, et al. (2008): Chemokines as pharmacological targets. Mini Rev Med Chem; 8(7):

References

638-46.

Ganoniig WE (1984): The brain renin-angiotensin system. *Annu Rev Physiol*; 46: 17.

Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003): N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. *Eur Heart J*; 24: 1735-43.

Garg R, Yusuf S (1995): Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. *JAMA*; 18: 1450-5.

Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V (2003): Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. *Circ Res* 93: 148-154

Gerstein HC et al. (2000): Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*; 355: 253-259.

Gerstein HC, Yusuf S, Bosch J et al. (2006): Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet*; 368:1096-

References

105.

Giannoccaro PJ, Wallace GJ, Higginson L, et al. (1989): Fatal angioedema associated with enalapril. *Can J Cardiol*; 5:335.

Gonzalez A, Lopez B, Querejeta R and Diez J (2002): Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? *Journal of Molecular and Cellular Cardiology*; 34: 1585-1593.

Goodfriend TL et al. (1998): Aldosterone in obesity. *Endocr Res*; 24: 789-796.

Goodfriend TL et al. (1999): Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. *Prostaglandins Leukot Essent Fatty Acids*; 60: 401-405.

Goodfriend TL, Elliott ME, Catt KJ (1996): Angiotensin receptors and their antagonists. *N Engl J Med*; 334: 1649.

Govindarajan G et al. (2006): Obesity and Hypertension: A clinical update. In eds, Ray R, Schiffrin E, and Sowers JR. *molecular mechanisms in hypertension*. Taylor and Francis Pub, London, 397-406.

Gradman AH, Vivas Y (2006): New drugs for hypertension: what do they offer? *Curr Hypertens Rep*; 8: 425-32.

References

- Granger JP et al. (1994):** Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. *Hypertension*; 23: I8-11.
- Gray MO, Long CS, Kalinyak JE, et al. (1998):** Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF- β 1 and endothelin-1 from fibroblasts. *Cardiovascular Research*; 40: 352-363.
- Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000):** Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. *Atherosclerosis Risk in Communities Study. N Engl J Med*; 342: 905-12.
- Griendling KK, Lassegue B, Alexander RW (1996):** Angiotensin receptors and their therapeutic implications. *Annu Rev Pharmacol Toxicol*; 36: 281.
- Guy JL, Lambert DW, Warner FJ, Hooper NM, Turner AJ (2005):** Membrane-associated zinc peptidase families: comparing ACE and ACE2. *Biochim Biophys Acta* 1751: 2-8
- Hamroff G, Katz SD, Mancithi D et al. (1999):** Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe compressive heart failure. *Circulation*; 99: 990-2.

References

- Han YP, Zhou L, Wang J, et al. (2004):** Essential role of matrix metalloproteinases in interleukin-1 induced myofibroblastic activation of hepatic stellate cell in collagen. *J Biol Chem*; 279(6): 4820-8.
- Hansson L, Lindholm LH, Niskanen L et al. (1999):** Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet*; 353: 611- 16.
- Harada K, Komuro I, Shiojima I, et al. (1998a):** Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. *Circulation*; 97: 1952-1959.
- Harada K, Komuro I, Zou Y, et al. (1998b):** Acute pressure overload could induce hypertrophic responses in the heart of angiotensin II type 1a knockout mice. *Circulation Research*; 82: 779-785.
- Harada K, Sugaya T, Murakami K, et al. (1999):** Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. *Circulation*; 100: 2093-2099.
- Harmer D, Gilbert M, Borman R, Clark KL (2002):** Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett*. 532: 107-110

References

- Harris RC (1999):** Potential mechanisms and physiologic actions of intracellular angiotensin II. *Am J Med. Sci.* 318: 374-389
- Harrison-Bernard LM, Zhou J, Kobori H, Ohishi M, Navar LG (2002):** Intrarenal AT₁ receptor and ACE binding in ANG II-induced hypertensive rats. *Am J Physiol* 281: F19-F25
- Hattori MA, Del Ben GL, Carmona AK, Casarini DE (2000):** Angiotensin I-converting enzyme isoforms (high and low molecular weight) in urine of premature and full-term infants. *Hypertension* 35: 1284-1290
- Heart Outcomes Prevention Evaluation Study Investigators (2000):** Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*; 355: 253-9.
- Helderman JH, Elahi D, Andersen DK et al. (1983):** Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. *Diabetes*; 32: 106-11.
- Helgeland A, Strommen R, Hagelund CH, Tretli S (1986):** Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. *Lancet* 1986; 1:872-5.
- Henriksen EJ, Jacob S (1995):** Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats.

References

Metabolism; 44: 267-72.

Henriksen EJ, Jacob S (2003): Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. *Diabetes Obes Metab*; 5: 214-22.

Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ (1999): ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. *Am J Physiol*; 277: R332-R336.

Henriksen EJ, Jacob S, Augustin HJ, Dietze CJ (1996): Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. *Diabetes*; 45 (suppl 1): S125-S128.

Herath CB, Warner FJ, Lubel JS, Dean R, Lew RA, Smith AI, Burrell LM and Angus PW (2006): The balance between hepatic ACE2 and ACE determines plasma levels of vasodilator peptide angiotensin (1-7) in experimental biliary fibrosis. *Journal of Gastroenterology and Hepatology*; 21(Suppl 4): A325.

Herings RM, de Boer A, Strieker BH, Leufkens HG, Porsius A (1995): Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. *Lancet*; 345: 1195-8.

Hhirose A, Ono M, Saibara T, et al. (2007): Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic

References

steatohepatitis. *Hepatology*; 45(6): 1375-81.

Higaki Y, Hirshman MF, Fujii N, Goodyear LJ (2001): Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. *Diabetes*; 50: 241-7.

Hoffmann S, Krause T, van Geel PP, et al. (2001): Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. *Journal of Molecular Medicine*; 79: 601-608.

Hoolenberg NK (2007): A brief response to Sealey and Laragh. *J Renin Angiotensin Aldosterone Syst*; 8: 53.

HOPE Investigators. Yusuf S, Sleight P, Pogue J, et al. (2000): The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. *N Engl J Med*; 342: 145.

Horing B, Kohler G, Drexler H (1997): Role of bradykinin in ?? vascular effects angiotensin-converting enzyme inhibitors in humans. *Circulation*; 35: 1115.

Hricik DE, Browning PJ, Kopelman R, et al. (1983): Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a

References

solitary kidney. *N Engl J Med*; 308: 373.

Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. (2004): Inflammatory markers and risk of developing type 2 diabetes in women. *Diabetes*; 53: 693-700.

Huang Y, Wongamomtham S, Kasting J, McQuillan D, Owens RT Yu L, Noble NA, Border W (2006): Renin increases mesangial cell transforming growth factor- β 1 matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. *Kid. Int.* 69: 105-113

Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM (2005): Angiotensin II AT1 receptors regulate ace2 and angiotensin-(1-7) expression in aorta of spontaneously hypertensive rats. *Am J Physiol* 289: H1013-H1019

Ikura Y, Ohsawa M, Shirai N, Sugama Y, Fukushima H, Suekane T, Hirayama M, Ehara S, Naruko T and Ueda M (2005): Expression of angiotensin II type I receptor in human cirrhotic livers: its relation to fibrosis and portal hypertension. *Hepatol Res*; 32(2): 107-16.

Inger C, Grima M, Coquard C, Barthelmebs M, Imbs JL (2002): Contribution of angiotensin II internalization to intrarenal angiotensin II levels in rats. *Am J Physiol* 283: 1003—1110

Isomaa B et al. (2001): Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*;

References

24(4): 683-689.

Iyer SN, Ferrario CM and Chappell MC (1998): Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. *Hypertension*; 31(1 Pt 2): 356-61.

Iyer SN, Ferrario CM, Chappell MC (1998): Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. *Hypertension* 31: 356-361

Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC (2000): Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. *J. Cardiovasc. Pharmacol.* 36: 109-217

Jamaluddin M, Meng T, Sun J, Boldogh I, Han Y and Brasier AR (2000): Angiotensin II induces nuclear factor (NF)-kappa B1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation. *Mol Endocrinol*; 14(1): 99-113.

Jandeleit-Dahm K and Cooper ME (2006): Hypertension and Diabetes: Role of the Renin-Angiotensin System. *Endocrinology and Metabolism Clinics of North America* 35; 469.

References

- Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM (2006):** Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. *Am J Physiol* 291: H2166-H2172
- Jett GK (1984):** Captopril-induced angioedema. *Ann Emerg Med*; 13: 489.
- K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification, and stratification (2002):** Kidney disease outcome quality initiative. *Am J Kidney Dis*; 39: S1-246.
- Kallis Y, Alison MR and Forbes SJ (2006):** Bone marrow stem cells and liver disease. *Gut*.
- Kang JJ, Toma I, Sipos A, McCulloch F, Peti-Peterdi J (2006):** Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy. *Adv Drug Deliv Rev*; 58: 824-33.
- Kannel WB, McGee DL (1979):** Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. *Diabetes Care* 2: 120-6.
- Kanno K, Tazuma S and Chayama K (2003):** AT1A-deficient mice show less severe progression of liver fibrosis induced by CC1(4). *Biochem Biophys Res Commun*; 308(1): 177-83.

References

- Kanno K, Tazuma S, Nishioka T, Hyogo H and Chayama K (2005):** Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. *Dig Dis Sci*; 50(5): 942-8.
- Keavney B, McKenzie C, Parish S, et al. (2000):** Large-scale test of hypothesized associations between the angiotensin-converting-enzyme insertion/ deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. *Lancet*; 355: 434.
- Keefe DL, Andersen K, Weinberger MH et al. (2007):** Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor. *J Am Coll Cardiol*; 49: 372A P-1014-204.
- Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z (2005):** Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. *Circ Res* 97: 946-953.
- Keidar S, Strizevsky A, Raz A, Gamliel-Lazarovich A (2006):** ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. *Nephrol Dial Transplant*: 1-5.
- Khan M Gabriel (2005):** Heart failure. In: *Heart Disease, Diagnosis and Therapy*. Totowa, NJ, Humana Press.

References

- Kim S and Iwao H (2000):** Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. *Pharmacological Reviews*; 52: 11-34.
- Kim YM, Guzik TJ, Zhang YH, et al. (2005):** A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. *Circ Res*; 97: 629-636.
- King H, Aubert RE, Herman WH (1998):** Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diabetes Care*; 21: 1414-31.
- Kiowski W, Beermann J, Rickenbacher P, et al. (1994):** Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. *Circulation*; 90: 2748-56.
- Klar J, Vitzhum H, Kurtz A (2004):** Aldosterone enhances renin expression in juxtaglomerular cells. *Am J Physiol* 286: F349-F355
- Klingbeil AU, Schneider M, Martus P, Messerli FH (2003):** A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med*; 115: 41.
- Klip A, Paquet MR (1990):** Glucose transport and glucose transporters in muscle and their metabolic regulation.

References

Diabetes Care; 13: 228-

Ko SH, Kwon HS, Kim SR et al. (2004): Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. *Biochem Biophys Res Commun*; 316: 114-22.

Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R, Fleming I (2002): CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. *Circ Res*. 91: 749-756

Kojima H, Tsujimoto T, Uemura M, Takaya A, Okamoto S, Ueda S, Nishio K, Miyamoto S, Kubo A, Minamino N, Kangawa K, Matsuo H and Fukui H (1998): Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. *J Hepatol*; 28(5): 840-6.

Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM and Thurman RG (2000): NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. *J Clin Invest*; 106(7): 867-72.

Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004): Omapatrilat and Enalapril in Patients With Hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. *Am J*

References

Hypertens 17: 111-121

Krum H (2008): Role of renin in heart failure and therapeutic potential of direct renin inhibition. *Journal of Renin-Angiotensin-Aldosterone System*, 9; 177.

Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM (2003): Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. *Clin Sci* 105: 339-345

Kurikawa N, Suga M, Kuroda S, Yamada K and Ishikawa H (2003): An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. *Br J Pharmacol*; 139(6): 1085-94.

Lakka HM et al. (2002): The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*; 288(21): 2709-2716.

Lakkis J, Lu WX, Weier MR (2003): RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. *Curr Hypertens Rep*; 5: 408-17.

Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ (2005): Tumor necrosis factor- α convertase (ADAM17) mediates

References

regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-Co-V) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280: 30113-30119

Latini R, Masson S, Anand I et al. (2002): Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation; 106: 2454-8.

Latini R, Masson S, Anand I et al. (2002): Valsartan Heart Failure Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation; 106: 2454-8.

Layoie JL and Sigmund CD (2003): Mini review: Overview of the Renin-Angiotensin System an Endocrine and Paracrine System. Endocrinology 144; 2179.

Leary WP, Reyes AJ (1987): Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther; 1: 29.

Leung PS and Chappell MC (2003): A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol; 35(6): 838-46.

Levy S (2006): Drug insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and

References

contraindications. *Nat Clin Pract Cardiovasc Med*; 3: 220-225.

Lewis EJ et al. (2001): Collaborative study group, renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*; 345(12): 851-860.

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med*; 329: 1456-62.

Lewis EJ, Hunsicker LG, Clarke WR et al. (2001): Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*; 345: 851-60.

Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD (2004): The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-T by rat proximal tubules. *Am J Physiol* 288: F353-F362

Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG (2006): Functional expression of the renin-angiotensin system in human podocytes. *Am J Physiol* 90: F710-F719

References

- Lindholm LH, Ibsen H, Dahlof B et al. (2002):** Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised-trial against atenolol. *Lancet*; 359: 1004-10.
- Linger T and Li J (2004):** The role of the renin-angiotensin-aldosterone system in heart failure. *Journal of Renin-Angiotensin-Aldosterone System* 5; S7.
- Lithell H, Hansson L, Skoog I et al. (2003):** The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens*; 21: 875-86.
- Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A and Roda E (2006):** Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. *World J Gastroenterol*; 12(45): 7239-49.
- Lubel JS, Herath CB, Warner FJ, Jia ZY, Burrell LM and Angus PW (2006):** Upregulation of the ACE2/Ang(1-7)/Mas receptor axis in the bile duct ligation (BDL) model of hepatic fibrosis does not affect hepatic sinusoidal resistance. *Journal of Gastroenterology and Hepatology*; 21(Suppl 4): A332.

References

- Lumbers ER (1999):** Angiotensin and aldosterone. *Regulatory Peptides* 80; 91.
- Lunde H, Hedner T, Samuelsson O, et al. (2007):** Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. *BMJ*; 308: 18.
- Mackins CJ, Kano S, Seyedi N, et al. (2006):** Cardiac mast cell-derived renin promotensive local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. *J Clin Invest*; 116: 1063.
- Madrid AH, Bueno MG, Rebollo JM, et al. (2002):** Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation*; 106: 331-336.
- Mailer S and Henriksen JH (2004):** pathogenesis and pathophysiology of hepatorenal syndrome - is there scope for prevention? *Alimentary Pharmacology and Therapeutics* 20; 31.
- Malendowicz SL, Ennezat PV, Testa M, et al. (2000):** Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. *Circulation*; 102: 2210.
- Malik S et al. (2004):** Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.

References

Circulation; 110(10): 1245-1250.

Marques GDM, Quinto BMR, Plavinik FL, Krieger JE, Marson O, Casarini DE (2003): N-domain angiotensin-I-converting enzyme with 80 kDa as a possible genetic marker of hypertension. Hypertension 42: 693-701

Marra F, Aleffi S, Bertolani C, et al. (2005): Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci; 9(5): 279-84.

Marre M, Leblanc H, Suarez L, Guvenne TT, Menard J, Passa R (1987): Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed); 294: 1448-52.

Mascareno E, El-Shafei M, Maulik N, et al. (2001): Jak/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation; 104: 325-329.

Massiera F et al. (2001): Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology; 142: 5220-5225.

Matsuno K, Yamada H, Iwata K, et al. (2005): Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation; 112: 2677.

Mazzolai L, Nussberger J, Aubert JF, et al. (1998): Blood pressure-independent cardiac hypertrophy induced by

References

locally activated renin-angiotensin system.
Hypertension; 31: 1324-1330.

Mazzolai L, Pedrazzini T, Nicoud F, et al. (2000): Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension; 35: 985-991.

McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nunez G and Lucas PC (2006): CARMA3/Bc110/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA.

McFarlane SI et al. (2001): Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab; 86(2): 713-718.

McKelvie RS, Rouleau JL, White M et al. (2003): Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur Heart J; 24: 1727-34.

McMurray J, Pitt B, Latini R, et al. (2008): Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail; 1: 17-24.

McMurray JJ, Ostergren J, Swedberg K, et al. (2003): CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-

References

ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*; 362: 767-71.

McMurray JJ, Stewart S (2000): Epidemiology, aetiology, and prognosis of heart failure. *Heart*; 83: 596-602.

McNamara DM, Holubkov R, Janosko K, et al. (2001): Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. *Circulation*; 103: 1644.

Meerson FZ, Belkina LM, Sazontova TG, et al. (1987): The role of lipid peroxidation in pathogenesis of arrhythmias and prevention of cardiac fibrillation with antioxidants. *Basic Res Cardiol*; 82: 123-137.

Menard J, Azizi M (2007): The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. *J Hypertens*; 25: 1775-82.

Menard J, Guyene TT, Peyrard S, Azizi M (2006): Conformational changes in prorenin during renin inhibition in vitro and in vivo. *J Hypertens*; 24: 529-34.

Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM (1993): Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. *J Cardiovasc Pharmacol*; 21: 791-6.

References

- Miyata T, Taguchi T, Uehara M et al. (1998):** Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. *Eur J Endocrinol*; 138: 344-52.
- Miyoshi M, Nagata K, Imoto T, Goto O, Ishida A and Watanabe T (2003):** ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats. *Am J Physiol Regul Integr Comp Physiol*; 284(4): R1092-7.
- Modrall JG, Sadjadi J, Brosnihan KB, Gallagher PE, Ya C-H, Bernstein KE, Chappell MC (2003):** Depletion of tissue ace differentially influences the intrarenal and urinary expression of angiotensins. *Hypertension* 43: 4849-4853
- Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ (2002):** Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. *Mol Endocrinol*; 16: 1931-42.
- Montgomery HE, Clarkson P, Dollery CM et al. (1997):** Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. *Circulation*; 96: 741.

References

- Moore MR Elliott TW, Nicholls MG. (1988):** Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. *Diabetes Care*; 11: 397-401.
- Morawietz H, Rueckschloss U, Niemann B, et al. (1999):** Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. *Circulation*; 100: 899.
- Moreno M and Bataller R (2008):** Cytokines and Renin-Angiotensin System Signaling in Hepatic Fibrosis. *Clinics in Liver Disease* 12; 825.
- Morris AD, Boyle DI, McMahon AD et al. (1997):** ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. *Diabetes Care*; 20:1363-7.
- Morris BJ, Iwamoto HS and Reid IA (1979):** Localization of angiotensinogen in rat liver by immunocytochemistry. *Endocrinology*; 105(3): 796-800.
- Munzel T, Keaney JF (2001):** Are ACE inhibitors a "magic bullet" against oxidative stress? *Circulation*; 104: 1571.
- Murdoch CE, Grieve DJ, Cave AC, et al. (2006):** NADPH oxidase and heart failure. *Curr Opin Pharmacol*; 6: 148-153.

References

- Murphey LJ, Gainer JV, Vaughan DE, Brown NJ (2000):** Angiotensin-converting enzyme insertion/ deletion polymorphism modulates the human in vivo metabolism of bradykinin. *Circulation*; 102: 829.
- Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M and Chayama K (2006):** Anti-fibrogenic function of angiotensin II type 2 receptor in CC14-induced liver fibrosis. *Biochem Biophys Res Commun*; 346(3): 658-64.
- Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K (2006):** Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. *Biochem Biophys Res Comm* 350: 1026-1031
- Nakagami H, Takemoto M, Liao JK (2007):** NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. *J Mol Cell Cardiol*; 35: 851-859.
- Nakagawa H, Daihara M, Tamakawa H, Nozue T, Kawahara K (1999):** Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. *J Cardiovasc Pharmacol*; 34: 28-33.
- Natali A, Bonadonna R, Santoro D et al. (1994):** Insulin resistance and vasodilation in essential hypertension. Studies with adenosine. *J Clin Invest*; 94: 1570-6.

References

- Natali A, Quinones Galvan A, Santoro D et al. (1993):** Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci (Lond); 85: 327-35.
- Natali A, Quinones Galvan A, Pecori N, Sanna G, Toschi E, Ferrannini E (1998):** Vasodilation with sodium nitroprusside does not improve insulin action in essential hypertension. Hypertension; 31: 632-6.
- Navalkan S, Parthasarathy S, Santanam N, Khan BV (2001):** Irebesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol; 37: 440.
- Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H (2002):** Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322
- Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, Packer M (1991):** Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol; 67: 63-6.
- Neuman RB, Bloom HL, Shukrullah I, et al. (2007):** Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem; 53: 1652-1657.
- Nguyen G (2006):** Renin/ prorenin receptors. Kidney Int; 69: 1503-06.

References

- Nguyen G, Delarue F, Burckle C, Bouzahir L, Giller T, Sraer JD (2002):** Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J Clin Invest* 109: 1417—1427
- Nicholls MG and Robertson JIS (2000):** The renin-angiotensin system in the year 2000. *Journal of Human Hypertension* 14; 649.
- Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L (2008):** Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. *Hypertension*; 51: 1306-11.
- Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002):** Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. *Hypertension*; 39: E1-8.
- Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL (2007):** Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. *J Am Coll Cardiol*; 49: 1157-63.
- O'Malley JP, Maslen CL, Illingworth R (1998):** Angiotensin converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. *Circulation*; 97: 1780.

References

- Omata M, Taniguchi H, Koya D, Kanasaki K, Sho R, Kato Y, Kojima R, Haneda M, Inomata N (2006):** N-Acetyl-Seryl-Aspartyl-Lysyl-Proline ameliorates the progression of renal dysfunction and fibrosis and WKY rats with established anti-glomerular basement membrane nephritis. *J Am Soc Nephrol* 17: 674-685
- Ondetti MA, Rubin B, Cushman DW (1977):** Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihyper-tensive agents. *Science*; 196: 441-4.
- Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O (1971):** Angiotensin-converting enzyme inhibitors from the venom of *Bothrops jararaca*. Isolation, elucidation of structure, and synthesis. *Biochemistry*; 10: 4033-9.
- Opie LH, Cersei B (2001):** *Drugs for the Heart*. Philadelphia, PA, US: WB Saunders.
- Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW (2006):** Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. *Am J Pathol* 168: 1808-1820
- Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K (2002):** Comparison of

References

omapatrilat and enalapril in patients with chronic heart failure. The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). *Circulation* 106: 920-926

Packer M, Coats AJ, Fowler MB et al. (2001): Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*; 344: 1651-8.

Pahor M et al. (2000): Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. *Diabetes Care*; 23: 888-892.

Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM and Angus PW (2002): Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. *Gastroenterology*; 123(5): 1667-76.

Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM and Angus PW (2005): Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. *Gut* 54(12): 1790-6.

Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M (1992): ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. *J Hum Hypertens*; 6: 175-9.

References

Parving HH et al. (2001): Irbesartan in Patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*; 345(12): 870-878.

Parving H-H, Lehnert H, Brochner-Mortensen J, et al. (2001): for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*; 345: 870.

Parying H (2000): Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus. *Journal of Renin-Angiotensin-Aldosterone System* 1; 30.

Pastore L, Tessitore A, Martinotti S, et al. (1999): Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. *Circulation*; 100: 1646.

Patlolla V, Alsheikh-Ali AA, Al Ahmad AM (2006): The renin-angiotensin system: a therapeutic target in atrial fibrillation. *Pacing Clin Electrophysiol*; 29: 1006-1012.

Paul M, Mehr AP, Kreutz R (2006): Physiology of local renin-angiotensin systems. *Physiol Rev* 86: 747-803

References

- Pendergrass KD, Averill DB, Ferrario CM, Diz DI, Chappell MC (2006):** Differential expression of nuclear ATI receptors and angiotensin TI within the kidney of the male congenic mRen2.Lewis rat. *Am J Physiol Renal Physiol* 290: F1497-F1506
- Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb NE (2003):** Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. *Hypertension* 42: 1164—1170
- Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB and Simoes ESAC (2006):** The renin-angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of Angiotensin-(1-7). *J Hepatol*.
- Petrie JR, Morris AD, Ueda S et al. (2000):** Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. *J Gin Endocrinol Metab*; 85: 1882-9.
- Petrie M, McMurray J (2001):** Changes in notions about heart failure. *Lancet*; 358: 432-4.
- Pfeffer MA, Swedberg K, Granger CB et al. (2003):** Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*; 362: 759-66.

References

- Pfeffer MA, Braunwald E (1990):** Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. *Circulation*; 81: 1161.
- Pfohl M, Koch M, Prescod S, et al. (1999):** Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study. *Eur Heart J*; 20: 1318.
- Piedrola G, Novo E, Serrano-Gotarredona J, de Teresa ML, Garcia-Robles R (1999):** Evolution of insulin resistance in coronary artery disease patients on four different pharmacological therapies. *Postgrad Med J*; 75: 27-31.
- Pilz B, Shagdarsuren E, Wellner M, et al. (2005):** Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. *Hypertension*; 46: 569-76.
- Pinzani M, Marra F (2001):** Cytokine receptors and signaling in hepatic stellate cells. *Semin Liver Dis*; 21(3): 397-416.
- Pitt B, Remme W, Zannad F, et al. (2003):** Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*; 348: 1309-1321.
- Pitt B, Remme W, Zannad F, et al. (2003):** Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*;

References

348: 1309-1321.

Pitt B, Zannad F, Remme WJ et al. (1999): The effect of spironelactone on morbidity and mortality in patients with severe heart failure. Randomized aldosterone evaluation study investigators. N Engl J Med; 341: 709-17.

Pitt B, Zannad F, Remme WJ, et al. (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med; 341: 709-17.

Pollare T, Lithell H, Berne C (1989): A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med; 321: 868-73.

Pollare T, Lithell H, Selinus I, Berne C (1989): Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ; 298: 1152-7.

Potter DD, Sobey CG, Tompkins PK, et al. (1998): Evidence that macrophages in and interleukin 6 in human coronary atherosclerotic plaques. Potential implications for inflammation and plaque instability. Circulation; 101: 1372.

References

- Powers AC. (2001):** Diabetes mellitus. In: Harrison's Principles of Internal Medicine, 15th ed. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL Eds. New York: McGraw-Hill, p. 2109-37.
- Priedman SL, Maher JJ and Bissell DM (2000):** Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology; 32(6): 1403-8.
- Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, Navar LG (2004):** Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 44: 223-229
- Pueyo ME, Michel JB (1997):** Angiotensin II receptors in receptors in endothelial cells. Gen Pharmacol; 29: 691.
- Raman VK, Lee YA, Lindpaintner K (1995):** The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol; 76: 18D.
- Raousseau A, Michaud A, Chauvet M-T, Lenfant M, Corvol P (1995):** The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270: 3656-3661

References

Reid IA (1985): The renin-angiotensin system and body function. Arch Intern Med; 145: 1475.

RENAAL study investigators. Brenner BM, Cooper ME, Zeeuw D de. et al. (2001): Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med; 345: 861.

Rett K, Wicklmayr M, Dietze CJ (1988): Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. N Engl J Med; 319: 1609.

Rett K, Wicklmayr M, Dietze CJ, Haring HU (1996): Insulin-induced glucose transporter (CLUT1 and CLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes; 45(suppl 1): S66-S69.

Reuben A (2008): Alcohol and the liver. Curr Opin Gastroenterol; 24(3): 328-38.

Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM (2006): Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48: 914-920

Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004): Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45-51

References

- Richoux JP, Cordonnier JL, Bouhnik J, Clauser E, Corvol P, Menard J and Grignon G (1983):** Immunocytochemical localization of angiotensinogen in rat liver and kidney. *Cell Tissue Res*; 233(2): 439-51.
- Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, Garcia-Retortillo M, Garcia-Valdecasas JC and Rodes J (2004):** Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. *Transplantation*; 78(5): 686-91.
- Rincon-Sanchez AR, Covarrubias A, Rivas-Estilla AM, Pedraza-Chaverri J, Cruz C, Islas-Carbajal MC, Panduro A, Estanes A and Armendariz-Borunda J (2005):** PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. *Exp Toxicol Pathol*; 56(4-5): 291-303.
- Rivera-Huizar S, Rincon-Sanchez AR, Covarrubias-Pinedo A, Islas-Carbajal MC, Gabriel-Ortiz G, Pedraza-Chaverri J, Alvarez-Rodriguez A, Mez-Garcia E and Armendariz-Borunda J (2006):** Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats. *Exp Toxicol Pathol*; 58(2-3): 185-95.
- Ron D, Brasier AR and Habener JF (1990):** Transcriptional regulation of hepatic angiotensinogen gene expression

References

by the acute-phase response. *Mol Cell Endocrinol*; 74(3): C97-104.

Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP and Forbes SJ (2006): The bone marrow functionally contributes to liver fibrosis. *Gastroenterology*; 130(6): 1807-21.

Sadjadi J, Kramer GL, Yu C, Welborn MB, Chappell MC, Modrall JG (2005a): Angiotensin converting enzyme-independent angiotensin II production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. *J Surg Res* 127: 65-69

Sadjadi J, Kramer GL, Yu CH, Welborn MB, Modrall JG (2005b): Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism. *J Surg Res* 129: 272-277

Saile B, Ramadori G (2007): Inflammation, damage repair and liver fibrosis-role of cytokines and different cell types. *Z Gastroenterol*; 45(1): 77-86.

Sakoda M, Ichihara A, Kaneshiro Y, et al. (2007): (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. *Hypertens Res*; 30: 1139-46.

References

Saltiel AR, Kahn CR. (2001): Insulin signaling and the regulation of glucose and lipid metabolism. *Nature*; 414: 799-806.

Sampaio WO, dos Santos RA, Faria-Silva R, de Mata Machado LT, Schiffrin EL, Touyz RM (2007): Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. *Hypertension* 49: 185-192

Sano M, Fukuda K, Kodama H, et al. (2000): Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. *Journal of Biological Chemistry*; 275: 29717-29723.

Santoro D, Natali A, Palombo C et al. (1992): Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. *Hypertension*; 20: 181-91.

Santos RA, Silva ACS, Marie C, Speth R, Machado RP de Buhr I, Heringer-Walther S, Pinheiro SVB, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003): Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci* 100: 8258-8263

Sasaki K, Taniguchi M, Miyoshi M, Goto O, Sato K and Watanabe T (2005): Are transcription factors NF-

References

kappaB and AP-1 involved in the ANG II-stimulated production of proinflammatory cytokines induced by LPS in dehydrated rats? *Am J Physiol Regul Integr Comp Physiol*; 289(6): R1599-608.

Scheen AJ (2004): Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. *Drugs*; 64: 2537-65.

Schiffrin EL (1999): Role of endothelin-1 in hypertension. *Hypertension* 34: 876—881

Schiffrin EL (2006): Effects of aldosterone on the vasculature. *Hypertension* 47: 312-318

Schmieder RE, Hilgers KF, Schlaich MP, et al. (2007): Renin-angiotensin system and cardiovascular risk. *Lancet*; 369: 1208-1219.

Schorr U et al. (1998): Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. *J Hypertens*; 16: 1475-1480.

Schuppan D, Ruehl M, Somasundaram R and Hahn EG (2001): Matrix as a modulator of hepatic fibrogenesis. *Semin Liver Dis*; 21(3): 351-72.

Scicli AG, Carretero OA (1986): Renal kallikrein-kinin system. *Kidney Int.* 29: 120-130

References

- Seed A, Gardner R, McMurray J, et al. (2007):** Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. *Eur J Heart Fail*; 9: 1120-7.
- Seefeldt T, Orskov L, Mengel A et al. (1990):** Lack of effects of angiotensin- « converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 | diabetes. *Diabet Med*; 7: 700-04. "
- Seki E, De Minicis S, Osterreicher CH, et al. (2007):** TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med*; 13(11): 1324-32.
- Senbonmatsu T, Ichihara S, Price E Jr, et al. (2000):** Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. *J Clin Invest*; 106: R25.
- Sepehrdad R, Frishman WH, Stier CT, Jr, et al. (2007):** Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. *Cardiol Rev*; 15: 242-256.
- Sernia C (2002):** A critical appraisal of the intrinsic pancreatic angiotensin-generating system. *JOP*; 2(1): 50-5.
- Sewnath ME, van der Poll T, van Noorden CJ, ten Kate FJ and Gouma DJ (2004):** Cholestatic interleukin-6-deficient mice succumb to endotoxin-induced liver injury and pulmonary inflammation. *Am J Respir Crit Care Med*; 169(3): 413-20.

References

- Shaltout HA, Westwood B, Averill DB, Ferrario CM, Figueroa J, Diz DI, Rose J, Chappell MC (2007):** Angiotensin Metabolism in Renal Proximal Tubules, Urine and Serum of Sheep: Evidence for ACE2-Dependent Processing of Angiotensin II. *Am J Physiol* 292: F82-F91
- Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T (1995):** The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. *Am J Hypertens*; 8: 276-81.
- Shepherd PR, Kahn BB (1999):** Glucose transporters and insulin action -implications for insulin resistance and diabetes mellitus. *N Engl J Med*; 341: 248-57.
- Shiuchi T, Cui TX, Wu L et al. (2002):** ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. *Hypertension*; 40:329-34.
- Sica D, Andersen K, Oh BH, Arora V, Bush C, Keefe DL (2008):** Effects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension. *J Clin Hypertens*; 10(suppl A): A34-5 P69.
- Silver RB, Reid AC, Mackins CJ, et al. (2004):** Mast cells: a unique source of renin. *Proc Natl Acad Sci USA*; 101: 13607.

References

- Skeggs LT, Jr, Kahn JR, Lentz K, Shumway NP (1957):** The preparation, purification, and amino acid sequence of a polypeptide renin substrate. *J Exp Med*; 106: 439-53.
- Skidgel RA, Erdos EG (2004):** Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. *Peptides* 25: 521-525
- Solomon S, Appelbaum E, Manning WJ, et al. (2008):** Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the Aliskiren left ventricular assessment of hypertrophy (ALLAY) Trial. Late Breaker presentation at American College of Cardiology; 57th Scientific Sessions.
- SOLVD Investigators (1991):** Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*; 325: 293.
- Song HJ, Lee TS, Jeong JH, et al. (2005):** Hydrogen peroxide-induced extracellular signal-regulated kinase activation in cultured feline ileal smooth muscle cells. *J Pharmacol Exp Ther*; 312: 391-398.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993):** Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor

References

Intervention Trial. Diabetes Care; 16: 434-44.

Stewart S, MacIntyre K, Macleod et al. (2001): Trends in hospitalization for heart failure in Scotland, 1990-1996. an epidemic that has reached its peak? Eur Heart J; 22: 209-17.

Stoll M, Steckelingd UM, Paul M, et al. (1995): The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest; 95: 651.

Strawn WB, Chappell MC, Dean RH, et al. (2000): Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation; 101: 1586.

Strawn WB, Dean RH, and Ferrario CM (2000): Novel mechanisms linking angiotensin II and early atherogenesis. Journal of Renin-Angiotensin-Aldosterone System 1; 11.

Su Z, Zimpelmann J, Bums KD (2006): Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 69: 2212—2218

Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP (2005): Mechanism of vasopeptidase inhibitor-induced plasma extravasation: Comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor

References

GW796406. J Pharm Exp Therapeutics 315: 1306-1313

Sun Y, Zhang J, Zhang JQ and Weber KT (2001): Renin expression at sites of repair in the infarcted rat heart. Journal of Molecular and Cellular Cardiology; 33: 995-1003.

Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y (1995): Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens; 17: 1257-68.

Suzuki S, Ohtomo M, Satoh Y et al. (1996): Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Diabetes Res Clin Pract; 33: 43-51.

Swedberg K, Eneroth P, Kjeksus J, Wilhelmsen L (1990): Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus trial study group. Circulation; 82: 1730-6.

Takase O, Marumo T, Imai N, Hirahashi J, Takayanagi A, Hishikawa K, Hayashi M, Shimizu N, Fujita T, Saruta T (2005): NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int 687464-473

References

- Tallant EA, Ferrario CM, Gallagher PE (2005a):** Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. *Am J Physiol* 289: H1560-H1566
- Tallant EA, Ferrario CM, Gallagher PE (2005b):** Differential regulation of cardiac angiotensin converting enzyme 2 (ACE2) and ACE by aldosterone. 46: 886 [Abstract],
- Tamura K, Chen YE, Chen Q, et al. (2000):** Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. *Molecular and Cellular Biochemistry*; 212: 203-209.
- Tang SS, Rogg H, Schumacher R and Dzau VJ (1992):** Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. *Endocrinology*; 131: 374-380.
- Tang WH, Vagelos RH, Yee YG, et al. (2002):** Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. *J Am Coll Cardiol*; 39(1): 70-8.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative / Research Group (2002):** Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium

References

channel blocker \s diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA; 288: 2981-97.

Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI, Thomas MC (2006): Developmental expression of ACE2 in the SHR kidney: A role in hypertension? Kidney Int 70: 34-41

Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME (2003): Characterization of renal Angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397 –

Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME (2002): Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens 20: 707—714

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000): A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243

Topol EJ, Thomas A, Fortuin NJ (1985): Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med; 312: 277.

References

- Torretti J (1982):** Sympathetic control of renin release. *Annu Rev Pharmacol Toxicol*; 22: 167.
- Tsikouris JP, Cox CD (2003):** Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. *Pharmacotherapy*; 23: 1141-52.
- Tsuruda T, Kato J, Kitamura K, et al. (2001):** Roles of protein kinase C and Ca²⁺- dependent signaling in angiotensin II-induced adrenomedullin production in rat cardiac myocytes. *Journal of Hypertension*; 19: 757-763.
- Tuomilehto J, Lindstrom J, Eriksson JG, et al. (2001):** Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*; 344: 1343-50.
- Turnbull F (2003):** Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. *Lancet*; 362: 1527-35.
- Ueda S, Meredith PA, Morton JJ, et al. (1998):** ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an Ace inhibitor drug (enalaprilat) in humans. *Circulation*; 98: 2148.
- Ueng KC, Tsai TP, Yu WC, et al.** Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of

References

long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J; 24: 2090-2098.

Varagic J, Frohlich ED (2003): Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol; 34(11): 1435-42.

Veelken R, Schmieder RE (2002): Neutral endopeptidase inhibition: the potential of the new therapeutic approach in cardiovascular disease evolves. J Hypertens 20: 599-603

Velloso LA, Foil! F, Sun XJ, White MF, Saad MJ, Kahn CR (1996): Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA; 93: 12490-5.

Vermes E, Tardif JC, Bourassa MG, et al. (2003): Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation; 107: 2926-2931.

Veterans Administration Cooperative Study Group on Antihypertensive Agents (1985): Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension; 7: 1008-16.

References

- Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P (2002):** Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 277: 14838-14843
- Vlachogiannakos J, Tang AK, Patch D and Burroughs AK (2001):** Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. *Gut*; 49(2): 303-8.
- Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S (2002):** The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. *J Am Soc Nephrol*; 13(suppl 3): S173-8.
- Wachtell K, Lehto M, Gerds E, et al. (2005):** Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for end point reduction in hypertension (LIFE) study. *J Am Coll Cardiol*; 45: 712-719.
- Waldmeier F, Glaenzel U, Wirz B, et al. (2007):** Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. *Drug Metab Dispos*; 35: 1418-28.

References

- Wang X, Desai K, Juulink BH, et al. (2006):** Gender-related differences in advanced glycation endproducts, oxidative stress markers and nitric oxide synthases in rats. *Kidney Int*; 69: 281-287.
- Wang XZ, Zhang LJ, Li D, Huang YH, Chen ZX and Li B (2003):** Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CC14. *World J Gastroenterol*; 9(3): 539-43.
- Wang YR, Alexander GC, Stafford RS (2007):** Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. *Arch Intern Med*; 167: 141-7.
- Weber KT (1999):** Aldosterone and spironolactone in heart failure. *N Engl J Med*; 341: 753.
- Weber MA, Giles TD (2006):** Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? *Rev Cardiovasc Med*; 7: 45-54.
- Wei H, Li D, Lu H, Zhan Y, Wang Z, Huang X, Pan Q and Xu Q (2000):** Effects of angiotensin II receptor blockade on hepatic fibrosis in rats *Zhonghua Gan Zang Bing Za Zhi*; 8(5): 302-4.
- Wei HS, Lu HM, Li DG, Zhan YT, Wang ZR, Huang X, Cheng JL and Xu QF (2000):** The regulatory role of AT1

References

receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CC1(4). *World J Gastroenterol*; 6(6): 824-828.

Wei YH, Jun L and Qiang CJ (2004): Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CC14 in rats. *Dig Dis Sci*; 49(10): 1589-94.

Weier MR, Dzau VJ (2000): The renin-angiotensin-aldosterone system: a specific target for hypertension management. *Am J Hypertens*; 12(12 Pt 3): 205S-213S.

Weir R, McMurray JJ (2005): Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. *Heart*; 91(suppl 2): ii17-20.

Westwood BM, Figueroa J, Rose JM, Chappell MC (2006): Distinct gender differences in the ACE2-dependent metabolism of angiotensin II in the serum of sheep. *Hypertension* 48: 46 [Abstract]

Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H (2002): AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. *Hypertension* 40: 847-852

Wing LM, Reid CM, Rvan P et al. (2003): A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. *N Enp J*

References

Med; 348: 583-92.

Wolf G (2006): Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. *Antioxid Redox Signal*; 7(9-10): 1337-45.

Wu S, Gao J, Ohlemeyer C, et al. (2005): Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. *Free Radic Biol Med*; 39: 160-1610.

Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Baffle D (2006): ACE and ACE2 activity in diabetic mice. *Diabetes* 55: 2132-2139

Yamada K, Iyer SN, Chappell MC, Brosnihan KB, Fukuhara M, Ferrario CM (1999): Differential response of angiotensin peptides in the urine of hypertensive animals. *Regul. Pept.* 80: 57-66

Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM (1998): Converting enzyme determines the plasma clearance of angiotensin-(1-7). *Hypertension* 98: 496-502

Yang BC, Phillips MI, Ambuehl PEJ, et al. (1997): Increase in angiotensin II type 1 receptor expression immediately after ischemia reperfusion in isolated rat hearts. *Circulation*; 96: 922.

Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA and Brenner DA (2005): Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor

References

deficient mice. J Hepatol; 43(2): 317-23.

Ye M, Wysocki J, William J, Soler MJ, Cokic I, Battle D (2006): Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminemia in diabetes. J Am Soc Nephrol 17: 3067-3075

Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M and Yoneda M (2006): Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol; 12(2): 322-6.

Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N and Nakamura K (2004): Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology; 40(5): 1222-5.

Yoshiji H, Kuriyama S and Fukui H (2002): Angiotensin-I-converting enzyme inhibitors may be an alternative anti-anitogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol; 23(6): 348-56.

Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H (2001): The angiotensin-I-converting enzyme inhibitor

References

perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res; 7(4): 1073-8.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H (2001): Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology; 34(4 Pt 1): 745-50.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H and Fukui H (2003): Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res; 27(1): 51-56.

Yoshiji H, Noguchi R and Fukui H (2005): Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol; 40(2): 215-6.

Yoshiji H, Noguchi R, Kuriyama S, Yoshii J and Ikenaka Y (2005): Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep; 13(3): 491-5.

Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S and

References

- Fukui H (2002):** Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. *J Hepatol*; 37(1): 22-30.
- Young ME, Radda CK, Leighton B (1997):** Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. *Biochem J*; 322(Pt1): 223-8.
- Yusuf S, Gerstein H, Hoogwerf B et al. (2001):** Ramipril and the development of diabetes. *KW* ; 286: 1882-5.
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000):** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*; 342: 145-53.
- Yusuf S, Sleight P, Pogue J, et al. (2000):** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*; 342: 145-153.
- Yusuf S, Sleight P, Pogue J, et al. (2000):** The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*; 342: 145-153.

References

- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais C (2000):** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*; 342: 145-53.
- Zaman AG, Keamey MT, Schecter C, et al. (2004):** Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. *Am Heart J*; 147: 823-827.
- Zhang L, Vincent MA, Richards SM et al. (2004):** Insulin sensitivity of muscle capillary recruitment in vivo. *Diabetes*; 53: 447-53.
- Zhang LJ, Zheng WD, Chen YX, et al. (2007):** Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. *Hepato-gastroenterology*; 54(79): 2092-8.
- Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS (2002):** Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta-1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. *J Am Soc. Nephrol.* 13: 302-312
- Zhang X, Yu WP, Gao L, Wei KB, Ju JL and Xu JZ (2004):** Effects of lipopolysaccharides stimulated Kupffer cells on activation of rat hepatic stellate cells. *World J*

References

Gastroenterol; 10(4): 610-3.

Zhang Y, Yang X, Wu P, Xu L, Liao G and Yang G (2003): Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production. Horm Res; 60(3): 105-10.

Zhang YJ, Yang XS, Wu PS, Li X, Zhang XF, Chen XQ and Yu ZX (2003): Effects of angiotensin II and losartan on the growth and proliferation of hepatic stellate cells. Di Yi Jun Yi Da Xue Xue Bao; 23(3): 219-21, 227.

Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K (2004): Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 44: 907-912

Zisman LS, Asano K, Dutcher DL, et al. (1998): Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation; 98: 1735.